High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 903-906

  Meisenberg, B ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

High dose chemotherapy; Melanoma; Stem cell support

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; IFOSFAMIDE; INTERFERON; INTERLEUKIN 2; MELPHALAN; NITROSOUREA; PLATINUM DERIVATIVE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SHORT SURVEY; SKIN TUMOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELANOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030018426     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30.
2. Kirkwood JM, Agarwala SS. Systemic cytotoxic and biologic therapy of melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer Principles and Practice of Oncology, 4th edn. JB Lippincott: Philadelphia, 1993, pp 1-16.
3. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50: 553-556.
4. Frei E, Cucchi CA, Rosowsky A et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 1985; 82: 2158-2162.
5. Schabel F, Trader M, Laster W et al. Patterns of resistence and therapeutic synergy among alkylating agents. Antiobiot Chemother 1978; 23: 200-215.
6. Ariel IM, Pack GT. Treatment of disseminated melanoma with phenylalanine mustard (melphalan) and autogenous bone marrow transplants. Surgery 1962; 51: 583-591.
7. Cornbleet MA, Mcelwain TJ, Kumar PJ et al. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer 1983; 48: 329-334.
8. Herzig RH, Wolff SN, Fay JW et al. Treatment of advanced melanoma with high-dose chemotherapy and autologous bone marrow transplantation. In: Dicke KA, Spitzer G, Jagannath S et al (eds). Autologous Bone Marrow Transplantation. Proc Fourth Int Symp. The University of Texas MD Anderson Cancer Center: Houston, 1989.
9. Thatcher N, Lind M, Morgenstern G et al. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 1989; 63: 1296-1302.
10. Wolff SN, Herzig RH, Fay JW et al. High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 1989; 7: 245-249.
11. Balch CM, Soong SJ, Murad TM et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastasis (stage II). Ann Surg 1981; 193: 377-388.
12. Gutterman JV, Scher MF. Melanoma. In: Holland J. Frei E (eds). Cancer Medicine. Lea & Febiger: Philadelphia, 1982, pp 2109-2140.
13. Meisenberg BR, Ross M, Vredenburgh JJ et al. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node positive malignant melanoma. J Natl Cancer Inst 1993; 85: 1080-1085.
14. Przepiorka D, Huh YO, Mehra R et al. Prolonged immunodeficiency in breast cancer patients after sequential high-dose chemotherapy with or without autologous marrow support. Blood 1993; 82 (Suppl. 1): 173a (Abstr.).
15. Talpaz M, Spitzer G. Low natural killer cell activity in the bone marrow of healthy donors with normal natural killer cell activity in the peripheral blood. Exp Hematol 1984; 12: 629-632.
16. Henon R, Liang H, Beck-Wirth G et al. Comparison of the hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285-291.
17. Neubauer MA, Benyunes MC, Thompson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994; 13: 311-316.
18. Higuchi CM, Thompson J, Bolonesi B et al. Phase Ib trial of interleukin-2 (IL-2) after autologous marrow transplantation (AMT) for hematologic malignancies. Proc Am Soc Clin Oncol 1990; 9: 17 (Abstr.).
19. Lister J, Rybka WB, Donnenberg AD et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate post-transplant period. Clin Cancer Res 1995; 1: 607-614.
20. McClay E, Albright K, Jones J et al. Tamoxifen (TAM) delays the development of resistance to cisplatin (DDP) in human malignancies. Proc Am Soc Clin Oncol 1993; 12: 132 (Abstr.).
21. Bailey HH, Mulcahy RT, Tutsch KD et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994; 12: 194-205.
22. Meisenberg B, McMillan R, Miller W. Sequential cycles of high-dose chemotherapy (HDC) with autologous peripheral blood progenitor cells (PBPC). Proc ASCO 1995; 14: 318 (Abstr.).
23. Crown J, Kritz A, Vahdat L et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993; 11: 1144-1149.
24. Lazarus HM, Herzig RH, Wolff SN et al. Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantation. Cancer Treat Rep 1985; 69: 473-477.
25. Shea TC, Antman KH, Eder JP et al. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol 1988; 124: 878-884.